Clearside Biomedical, Inc., an Alpharetta, GA-based clinical-stage biopharmaceutical company developing drug therapies to treat blinding diseases of the eye, closed a $20m Series C financing.
Backers included new investors Aju IB Investment, Cormorant Asset Management, Perceptive Advisors and Rock Springs Capital Management, as well as existing investors.
The company will use the funds to advance the clinical development of its pipeline to treat blinding diseases like uveitis, retinal vein occlusion and wet age-related macular degeneration.
Led by Daniel H. White, CEO and President, Clearside Biomedical develops drug therapies to treat blinding diseases of the eye using proprietary microinjector to reach diseased tissue. The company holds intellectual property protecting the delivery of drugs of any type through the SCS™ (suprachoroidal space) to reach the back of the eye.